Clinical Research vs Recreational Use
How supervised clinical research with psychedelic and related drugs differs from nonmedical use, and why safety findings from trials cannot be applied to unsupervised use.
Content last updated . This page has not been medically reviewed.
Urgent first
If someone is in a frightening or dangerous state after taking any substance, call 911 in the US. For suspected poisoning, Poison Help is 1-800-222-1222. The 988 Suicide and Crisis Lifeline is available in the US for emotional crisis. See When to Seek Urgent Help.Two very different situations
Most of what the public hears about psychedelics comes from one of two worlds: supervised clinical research, and nonmedical use. They differ in who takes part, what substance is given, what support exists, and how harms are tracked.The US National Institute on Drug Abuse (NIDA) notes that most people who report using psychedelic and dissociative drugs do so outside of medical or research settings. [1]
Side-by-side
| Clinical research | Nonmedical use | |
|---|---|---|
| Who takes part | Screened volunteers or patients. Modern research excludes people with previously diagnosed psychosis or bipolar disorder, and sometimes other mental illnesses, as a precaution. [1] | No research team screens who takes part. |
| What is taken | A defined study product with known content, under regulatory oversight. FDA's guidance applies the same regulations and evidentiary standards as for other drugs. [2] | NIDA warns that illicitly manufactured or processed drugs may be contaminated with colorless and odorless fentanyl or other dangerous substances. [1] |
| Support | Trained monitors. FDA notes that people receiving active treatment may remain vulnerable for several hours or longer. [2] | Often none. NIDA says injuries and safety issues are more likely if no one else is present who can help. [1] |
| Tracking of harms | Adverse events are recorded, although NIDA says many past studies did not adequately assess or report them. [1] | NIDA says reported cases likely represent only a very small number of people, and most people who use these drugs do not seek emergency services. [1] |
| What is known | Serious adverse events from professionally supervised use are reported as relatively low. [1] | NIDA says further research is needed on the health and safety impact of typical use, and that poor mental health outcomes may be more likely outside clinical use. [1] |
How research teams reduce risk
A 2008 paper from Johns Hopkins researchers on safety in human hallucinogen research explains the main risks: overwhelming distress during the drug's effect, which can lead to potentially dangerous behavior such as leaving the study site; less commonly, prolonged psychosis; and rarely, persisting perception changes. It describes safeguards used in research, including excluding volunteers with personal or family history of psychotic disorders or other severe psychiatric disorders, building trust before sessions, careful preparation, a safe physical environment and support from at least two monitors. [3] This describes how a research team protects participants. It is not a plan for anyone to arrange a session elsewhere, and this site does not provide one.Why trial safety does not transfer
NIDA states that mental health complications are currently extremely rare in clinical research settings in part because studies are highly controlled and participants are screened. [1] When screening, a defined product and monitoring are missing, the trial safety record cannot simply be carried over. This is a limit on what the evidence can show. Label: insufficient evidence on the safety of typical nonmedical use, as NIDA says more research is needed. [1]Challenging experiences
NIDA cites a survey of almost 2,000 people who took psilocybin outside a medical setting and had a challenging experience; 11% said they had put themselves or others at risk of harm. [1] Survey data like this rely on self-report and cannot show how common such events are.Regulatory and legal difference
Being studied in a trial, receiving a regulatory designation, or using a substance under a state program is not the same as general medical approval. NIDA's page states that only esketamine is FDA approved for therapeutic use to date, and that FDA has granted Breakthrough Therapy designation to two psilocybin formulations in study for depression. [4] See Medical Approval: What Is and Is Not Approved and Psychedelic Legal Status.Education only
This page compares settings. It does not recommend nonmedical use, give amounts, or tell anyone how to take part in or arrange care. To learn about legitimate studies, see Finding and Understanding Registered Clinical Trials. For psychological safety in particular, see Acute Psychological Distress.Frequently asked questions
Are clinical trial results proof that nonmedical use is safe?
No. NIDA says trials are highly controlled and screen participants, so their safety record does not describe unsupervised use. [1]
Why are some people excluded from research?
As a precaution, modern research excludes participants with previously diagnosed psychosis or bipolar disorder, and sometimes other mental illnesses. [1]
Is contamination a concern outside research?
NIDA says illicitly made drugs may be contaminated with fentanyl or other dangerous substances. [1]
Does "clinical" mean "approved"?
No. A study or a designation is not an approval. [4]
Do research safeguards mean the drugs are low risk?
Not in general. Reviewers describe real risks even in research, such as overwhelming distress and, less commonly, prolonged psychosis, which is why safeguards exist. [3]
References
- National Institute on Drug Abuse, Psychedelic and Dissociative Drugs. Read 2026-10-22.
- US Food and Drug Administration, Psychedelic Drugs: Considerations for Clinical Investigations, Guidance for Industry (July 2026). Read 2026-10-22.
- Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603-20. Read 2026-10-22 (abstract on PubMed).
- National Institute on Drug Abuse, Psychedelic and Dissociative Drugs as Medicines. Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.